Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$12.78 ▼ -0.15
(-1.16%)
MKT CAP: $706.0M • VOL: 848.9K
52W L $7 52W H $17
FDMT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $85.2M | $37.0K | $20.7M |
| YoY Revenue Growth % | +230194.6% | -99.8% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$159.5M | -$187.8M | -$112.9M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$140.1M | -$160.9M | -$100.8M |
| EBITDA (Normalized) | -$159.1M | -$184.8M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$109.1M | -$134.6M | -$75.8M |
| Capital Expenditures (CapEx) | $536.0K | $3.8M | — |
| Free Cash Flow (FCF) | -$109.6M | -$138.4M | -$75.8M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -28.3% | -41.1% | — |
| Cash & Short-Term Equivalents | $60.2M | $149.3M | — |
| Total Debt (Short + Long Term) | $0 | — | — |
| Total Stockholders' Equity | $505.7M | $510.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR FDMT.